Cabenuva Kit Patent Expiration

CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6838464 VIIV HLTHCARE 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
Feb, 2021

(3 years ago)

US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(1 year, 3 months ago)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(9 months from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(1 year, 9 months from now)

US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(1 year, 9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(2 years from now)

US11224597 VIIV HLTHCARE Pharmaceutical compositions
Sep, 2031

(7 years from now)



Cabenuva Kit is a drug owned by Viiv Healthcare Co. It is used for treating HIV-1 infection in adults and adolescents aged 12 years and older. Cabenuva Kit uses Cabotegravir; Rilpivirine as an active ingredient. Cabenuva Kit was launched by Viiv Hlthcare in 2021. It is is available in suspension, extended release form for intramuscular use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 15, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-184) Jan 31, 2025
New Patient Population(NPP) Mar 29, 2025
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy; Treatme...

Dosage: SUSPENSION, EXTENDED RELEASE

More Information on Dosage

CABENUVA KIT family patents

Family Patents